PP
RCUS icon

PDT Partners’s Arcus Biosciences RCUS Stock Holding History

PDT Partners’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.39M Hold
388,338
– – 0.5% 53
2025
Q4 		$9.25M Hold
388,338
– – 0.6% 28
2025
Q3 		$5.28M Sell
388,338
-949
-0.2% -$9.87K 0.33% 93
2025
Q2 		$3.17M Buy
389,287
+298,989
+331% +$2.55M 0.18% 200
2025
Q1 		$709K Sell
90,298
-35,454
-28% -$411K 0.05% 461
2024
Q4 		$1.87M Buy
125,752
+38,116
+43% +$622K 0.17% 221
2024
Q3 		$1.34M Buy
87,636
+14,371
+20% +$227K 0.12% 306
2024
Q2 		$1.12M Sell
73,265
-23,887
-25% -$386K 0.11% 315
2024
Q1 		$1.83M Buy
97,152
+82,178
+549% +$1.42M 0.17% 209
2023
Q4 		$286K Buy
+14,974
New +$239K 0.03% 468
2023
Q2 		– Sell
-51,925
Closed -$947K – 637
2023
Q1 		$947K Buy
51,925
+13,298
+34% +$254K 0.13% 275
2022
Q4 		$799K Sell
38,627
-19,901
-34% -$548K 0.13% 292
2022
Q3 		$1.53M Buy
58,528
+30,910
+112% +$817K 0.23% 109
2022
Q2 		$700K Buy
+27,618
New +$676K 0.06% 512
2022
Q1 		– Sell
-5,051
Closed -$204K – 1078
2021
Q4 		$204K Buy
+5,051
New +$196K 0.02% 762
2020
Q4 		– Sell
-24,247
Closed -$416K – 830
2020
Q3 		$416K Buy
+24,247
New +$542K 0.03% 486
2020
Q2 		– Sell
-17,033
Closed -$236K – 793
2020
Q1 		$236K Sell
17,033
-2,529
-13% -$31.5K 0.02% 526
2019
Q4 		$198K Sell
19,562
-3,538
-15% -$29.8K 0.01% 651
2019
Q3 		$210K Buy
23,100
+6,400
+38% +$51.4K 0.01% 410
2019
Q2 		$133K Buy
+16,700
New +$167K 0.01% 393

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

PDT Partners's RCUS Position: Q1 2026 in Review

PDT Partners held its Arcus Biosciences (RCUS) position steady in Q1 2026 at 388,338 shares worth $8.39M. The position accounts for 0.5% of the portfolio, ranked #53.

PDT Partners first reported a position in RCUS in Q2 2019 and has held it in 20 quarters since. The position peaked at $9.25M in Q4 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • PDT Partners held 388,338 shares of Arcus Biosciences worth $8.39M as of Q1 2026.
  • PDT Partners left its Arcus Biosciences share count unchanged in Q1 2026.
  • Arcus Biosciences made up 0.5% of PDT Partners's portfolio in Q1 2026, its #53 holding.
  • PDT Partners first reported a position in Arcus Biosciences in Q2 2019 and has held it in 20 quarters since.
  • PDT Partners's Arcus Biosciences position peaked at $9.25M in Q4 2025.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on PDT Partners's 13F filing for Q1 2026, filed 15 May 2026.